US20040146593A1 - Herbal drug composition for cartilage protection - Google Patents

Herbal drug composition for cartilage protection Download PDF

Info

Publication number
US20040146593A1
US20040146593A1 US10/478,048 US47804803A US2004146593A1 US 20040146593 A1 US20040146593 A1 US 20040146593A1 US 47804803 A US47804803 A US 47804803A US 2004146593 A1 US2004146593 A1 US 2004146593A1
Authority
US
United States
Prior art keywords
herbal
cartilage
drug composition
acid
radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/478,048
Inventor
Chang-kyun Han
Wie-jong Kwak
Ki Joung
Hun Yoo
Do Kum
Yong-Baik Cho
Keun Ryu
Hae Rhee
Taek Kim
In Jung
So Lee
Jung Yi
Joo-Hyon Kim
Key Um
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Chemicals Co Ltd
Original Assignee
SK Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19709626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040146593(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Chemicals Co Ltd filed Critical SK Chemicals Co Ltd
Assigned to SK CHEMICALS CO., LTD. reassignment SK CHEMICALS CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHO, YONG-BAIK, HAN, CHANG-KYUN, JOUNG, KI WON, JUNG, IN HO, KIM, JOO HYON, KIM, TAEK SU, KUM, DO SEUNG, KWAK, WIE-JONG, LEE, SO YOON, RHEE, HAE IN, RYU, KEUN HO, UM, KEY AN, YI, JUNG BUM, YOO, HUN SEUNG
Publication of US20040146593A1 publication Critical patent/US20040146593A1/en
Priority to US13/400,784 priority Critical patent/US8652537B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536—Prunella or Brunella (selfheal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/716—Clematis (leather flower)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention relates to a herbal drug composition for cartilage protection and more particularly, to the drug composition for cartilage protection comprising plant extracts of Clematis Radix, Trichosanthis Radix, and Prunellae Spica and an optimal content of rosmarinic acid to: (i) alleviate pains; (ii) inhibit the acute/chronic inflammation, platelet/whole blood aggregation, immunocyte (B-lymphocyte and T-lymphocyte) proliferation, inflammation-inducing enzyme activities, and enzyme activities associated with degradation of joint tissue; (iii) scavenge activity of toxic active oxygen radicals; and (iv) further provide excellent cartilage protection activity to be effectively used as an anti-inflammatory agent with analgesic effects, blood circulation enhancer, arthritis therapeutic agent and cartilage protective.
  • Clematis Radix, Trichosanthis Radix, and Prunellae Spica are well known for medicinal plants. Each medicinal plant has long been used for the treatment of general inflammations, such as various swellings, wounds, bronchitis, mastitis, tonsillitis, and anal fistula and also for the relief of various symptoms such as cold or numb hands, painful knees, painful waist and shoulder, feeble in health and pain in the skin, in the form of aqueous plant extract. These symptoms are similar to general arthritis including chronic rheumatism in terms of the modern pathological concept. Clematis Radix, a root of Clematis mandshurica and the same genera in plant taxonomy, is distributed in the shady forest throughout Asia.
  • Clematis Radix a non-toxic medicinal plant, has long been used for the treatment of the following symptoms: pains in the extremities; motor disturbance in knee joints; and paralysis in the extremities.
  • Clematis Radix has been frequently used as a spontaneous drug in those patients who feel uncomfortable while standing due to the coldness in waist, knees and feet. It is well known that Clematis Radix has various constituents of flavanone glycosides such as clematin, etc.
  • Trichosanthis Radix known as “multifarious medicine” or “Karokon”, is a non-toxic medicinal herb prepared by collecting roots of Trichosnathes kirilowii and the same genera in plant taxonomy, which are perennial liana plants, in autumn. The outer shells of cleanly washed roots are removed and the rest of the roots are cut appropriately and dried in the sun for medicinal use. Trichosanthis Radix has been widely used for excretion of pus, vanishing the boil, detoxification and antipyretic effect and also effective for diseases symptomized by thirst, various swellings, mastitis, and anal fistula.
  • Trichosanthis Radix contains trichosanthin as proteins, arginine and citruline as amino acids, and palmitic acid and linoleic acid as fatty acids. Recently Trichosanthis Radix is found to contain bryonolic acid, 4-hydroxybenzoic acid, ⁇ -spinastero as sterols [Research Archives of Useful Plants Resources in Korea, Korea Research Institute of Chemical Technology, pp 354-357(1988), 2. An Explanatory Diagram of Korean Medicinal Plants, Youngrim Pub., pp960-963(1990)].
  • Prunellae Spica a flower or upper part of Prunella vulgaris and the same genera in plant taxonomy, is a non-toxic medicinal herb prepared by collecting the flower, when it is half withered during summer, and drying in the sun. Prunellae Spica has been widely used for the treatment of the following symptoms: chronic swellings, smallpox, acute mastitis and lymphatic tuberculosis. Prunellae Spica is also effective in the destructing lumps (generated in a lower stomach owing to extravasated blood) or others, while treating beriberi and numbness in the extremities.
  • Prunellae Spica contains saponins such as oleanolic acid glycosides and ursolic acid glycosides, etc, and also contains carotene, vitamin C, vitamin K, tannin, caffeic acid and chlorogenic acid. Rosmarinic acid is also found in Prunellae Spica [Research Archives of Useful Plant Resources in Korea, Korea Research institute of Chemical Technology, pp 480-482(1988); Chemical Research for Prunellae Spica, Lee Jak-pyung et al., Bulletin of Medical College in Beijing, 17(4), pp297-299(1985); Pharm. Acta. Helv., 66, No. 7, pp185-188(1991)].
  • the conventional oriental herbal books e.g., Dong-Eui-Bo-gam, Hyangyak Gibsung-bang and Kwangjee Beakub
  • related literatures refer to the medical efficacy of herbs and processes of manufacturing aqueous herbal solutions.
  • they only described a single prescription of each of these medicinal plants but not a formulation available for the manufacture of aqueous herbal solution from appropriate combinations of sorted medicinal plants by harvest place and harvest time to control the content of active ingredients.
  • these medicinal plants were prepared by hot water extraction method, and any substances extracted by above method showed no acquisition of detailed knowledge on biologically active ingredients.
  • the inventors of the present invention have disclosed a process of extraction and purified biologically effective ingredients from an extract of Clematis Radix, Trichosanthis Radix, and Prunellae Spica in a certain ratio, being useful for alleviating acute/chronic inflammation; for inhibiting platelet and whole blood aggregation, enzyme activities associated with degradation of joint tissue, abnormally proliferated immunocytes, and inflammation-inducing enzymes; for scavenging activity of toxic active oxygen radical; and further for the treatment of chronic rheumatoid arthritis (U.S. Pat. No. 5,910,307).
  • 5,910,307 is characterized by mixing Clematis Radix, Trichosanthis Radix, and Prunellae Spica in a weight ratio of 1:0.5-2:0.5-1.5 and extracting the mixture with water or aqueous alcoholic solution; partitioning with water-saturated n-butanol and concentrating the alcohol layer under reduced pressure; and concentrating the result with water under constant boiling and lyophilizing to obtain an extract in powder form.
  • the present invention provides significant improvement in merchandizing by optimizing the herbal extract composition of Clematis Radix, Trichosanthis Radix, and Prunellae Spica with the proper content of rosmarinic acid, maximizes pharmacological efficiencies over the conventional herbal composition and further provides novel therapeutic effects.
  • the present invention is to provide a herbal drug composition
  • a herbal drug composition comprising Clematis Radix, Trichosanthis Radix, and Prunellae, wherein the ingredients extracted and purified are standardized and merchandized based on the content of rosmarinic acid for the purpose of reproducibility and useful for an anti-inflammatory agent with analgesic effects, blood circulation enhancer, arthritis therapeutic agent and cartilage protective, etc.
  • the herbal drug composition of the present invention has similar or superior efficiency for analgesic and anti-inflammatory effect and improving blood circulation to the conventional herbal composition of U.S. Pat. No. 5,910,307. In addition to that, it has excellent inhibitory activities against enzymes associated with degradation of joint tissue and a protection activity toward cartilage and thus, it is superiorly effective to general arthritis including rheumatism.
  • the object of the present invention is to provide a herbal drug composition having excellent analgesic and anti-inflammatory effect, improving effect of peripheral blood circulation, arthritis therapeutic effect and cartilage protection effect by standardizing the extracts from mixed Clematis Radix, Trichosanthis Radix, and Prunellae Spica with the proper content of rosmarinic acid.
  • FIG. 1 represents the inhibitory activity of the herbal drug composition on edema induced by carrageenan.
  • FIG. 2 represents the anti-coagulant activity of the herbal drug composition on platelet aggregation.
  • FIG. 3 represents the anti-coagulant activity of the herbal drug composition on whole blood aggregation.
  • FIG. 4 represents the inhibitory activity of the herbal drug composition on chronic inflammation.
  • FIG. 5 represents the inhibitory activity of the herbal drug composition on B-lymphocyte proliferation.
  • FIG. 6 represents the inhibitory activity of the herbal drug composition on T-lymphocyte proliferation.
  • the present invention is characterized by a combined herbal drug composition comprising Clematis Radix, Trichosanthis Radix, Prunellae Spica and more than 0.6 wt. % of rosmarinic acid based on the total composition.
  • the herbal drug composition of the present invention provides significant biological effects such as analgesic and anti-inflammations, improvement of blood circulation, immunoregulation and inhibitions on enzymes associated with degradation of joint tissue, and particularly, cartilage protection and thus, being useful as arthritis therapeutic agent and cartilage protective as well as an analgesic and anti-inflammatory agent and blood circulation enhancer.
  • the present invention is characterized by selecting rosmarinic acid as a reference material to obtain the herbal drug composition with optimal pharmacological efficiency.
  • Rosmarinic acid is known to have excellent activities such as: (i) antioxidant activity by inhibiting lipid peroxidation and/or biosynthesis of prostacyclin generated in the metabolism of arachidonic acid, and by scavenging the active oxygen generated from polymorphonuclear leukocytes; (ii) anti-inflammatory activity such as inhibition against the generation of metabolites which are carriers for inflammation reaction and immunoregulation to inhibit allergic inflammation; (iii) blood circulation enhancing activity by inhibition of platelet blood aggregation and fiber degradation [ Agent and Action, 17, pp375-376(1985); Pharm. Acta.
  • the herbal drug composition of the present invention can be prepared by mixing the herbal extracts of Clematis Radix, Trichosanthis Radix, Prunellae Spica or extracting the mixture of Clematis Radix, Trichosanthis Radix, Prunellae Spica not depending on the weight ratio of each herbal plant but depending on the content of rosmarinic acid contained in the total herbal plants.
  • the herbal drug composition can obtain the desired pharmaceutical efficiencies when the content of rosmarinic acid is higher than 0.6 wt. % of rosmarinic acid, preferably 0.6-5.0 wt. %.
  • the content of rosmarinic acid is higher than 0.6 wt. % in the herbal drug composition comprising Clematis Radix, Trichosanthis Radix, Prunellae Spica, it provides optimal effects such as cartilage protection activity which has not been taught in the conventional herbal drug compositions as well as alleviation of pains, improvement of blood circulation, immunoregulation, and inhibition of enzymes associated with degradation of joint tissue. If the content of rosmarinic acid is lower than 0.6 wt.
  • the herbal drug composition provides alleviation of pains, improvement of blood circulation, immunoregulation, and inhibition of enzymes associated with degradation of joint tissue but very sluggish cartilage protection activity.
  • the present invention has no upper limitation for the amount of the rosmarinic acid but when it is higher than a certain level, the activities are not improved any further, thus it is not desirable technically and economically to increase the content of rosmarinic acid to higher than a certain level.
  • the herbal drug composition when the herbal drug composition contains 2.0-6.0 wt. % of oleanolic acid and 0.01-0.04 wt. % of 4-hydroxybenzoic acid in addition to higher than 0.6 wt. % of rosmarinic acid, it provides far more potent efficacy toward cartilage protection activity as well as alleviation of pains, improvement of blood circulation, immunoregulation, and inhibition of enzymes associated with degradation of joint tissue.
  • oleanolic acid Large quantity of oleanolic acid is present in the extract of Clematis Radix. When the extract is hydrolyzed, sufficient amounts of oleanolic acid are present as a sapogenin, a sugar-free form of saponins. According to an analysis, it is found that oleanolic acid is present as saponins bonded to various glycosides. It has been reported that oleanolic acid has not only remarkable anti-inflammatory and analgesic effects but also an excellent effect for chronic rheumatoid arthritis induced by Mycobacterium butyricum [J. of Pharm.
  • the extract of Trichosanthis Radix contains various organic acids including 4-hydroxybenzoic acid.
  • 4-hydroxybenzoic acid is known to have excellent anti-oxidant activity, anti-inflammatory activity and hormone-like effect in the uterus ablation osteoporotic model and further is one of reference materials for the present invention because it is maintained in a certain amount regardless of harvest place, harvest time, storage period and storage conditions [ Free Radical Biol. & Medcine, 27, No.11/12, pp1427-1436(1999); J. Ethnopharma., 53, 11-14(1996); Environ. Res., 75, pp130-134(1997)].
  • Rosmarinic acid, oleanolic acid and 4-hydroxybenzoic acid selected as reference materials are active ingredients of herbal drug composition obtained from this invention.
  • the efficacy is far more potent due to remarkable synergic effect when they are combined in a certain ratio based on the contents of active ingredients. Further, in addition to such active ingredients of the herbal drug composition from this invention, other different ingredients cannot be ruled out in this invention.
  • the herbal drug composition of the present invention is prepared by either mixing each extract in powder form of Clematis Radix, Trichosanthis Radix, and Prunellae or extracting the mixture of Clematis Radix, Trichosanthis Radix, and Prunellae Spica based on the chemical analysis of original herbal plants.
  • the method for preparing herbal drug composition makes a little difference in cartilage protection activity. The method for preparing herbal drug composition is described in detail as set forth hereunder.
  • Each Clematis Radix, Trichosanthis Radix, and Prunellae Spica or a mixture thereof is extracted with 5-10 volumes of water or aqueous alcoholic solution under reflux for 4 to 6 hours and filtered.
  • the filtrate is further extracted with 5-10 volumes of water or aqueous alcoholic solution under reflux and filtered.
  • Each extract is combined and concentrated to dryness.
  • the solvent if a small amount of the solvent is used, the extraction efficiency is low due to the lower solubility of extract and the difficulty of stirring the extract.
  • a larger amount of solvent saturated with lower alcohol in water has to be evaporated and removed, therefore which is uneconomical and difficult in handling.
  • the present invention performs a series of extraction steps, i.e., first and second extraction, because when the extraction is on a large scale, significant losses are anticipated due to high contents of water in medicinal plants, in spite of effective filtration. So the second extraction is responsible for preventing the reduced extraction efficiency rather than the first extraction only. Further, it is revealed that about 85-95% of the total extract amount is obtained through two extractions. It is also found that more than three steps of extraction are not to be desirable in economical matter.
  • the extracts are filtered and concentrated, and the filtrate is purified to remove some impurities such as proteins, polysaccharides and fatty acids by extracting with the same amount of lower alcohol saturated with 3-4 volumes of water.
  • lower alcohol used in the present invention include butyl alcohol and propyl alcohol. If the amount of water-saturated lower alcohol is less than that of the filtrate, a higher concentration of impurities (e.g., polysaccharides, and proteins) having relatively strong polarity causes lower concentration of active ingredients in the extracts due to poor separation of layers.
  • the obtained fractions extracted with alcohol are concentrated under reduced pressure at 60-70° C. to remove lower alcohol in the sample. Then, the extract is further concentrated 2-3 times under constant boiling with 25-50 volumes of water to the total extract amount and followed with another same amount of water for homogeneous suspension. The reason why the residue is concentrated under constant boiling with water is to control the contents of remaining lower alcohol so as to use the extracting solution as pharmaceutical raw materials.
  • the obtained extract is then lyophilized to give an extract powder.
  • the obtained extract powder has significant pharmacological effects, such as analgesic and anti-inflammatory agents, blood circulation enhancers, rheumatoid arthritis therapeutic agents, and cartilage protection agents.
  • the powdered extract of this invention is formulated in oral or parenteral administration such as tablets, soft gelatin capsules, injection solutions, ointments, and transdermals.
  • the herbal drug composition of this invention can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • the herbal drug composition may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents.
  • Such liquid preparations may be prepared with pharmaceutically acceptable additives such as suspending agent (e.g., methylcellulose, a semi-synthetic glyceride such as witepsol or mixtures of glycerides such as a mixture of apricot kernel oil and PEG-6 esters or mixtures of PEG-8 and caprylic/capric glycerides).
  • suspending agent e.g., methylcellulose, a semi-synthetic glyceride such as witepsol or mixtures of glycerides such as a mixture of apricot kernel oil and PEG-6 esters or mixtures of PEG-8 and caprylic/capric glycerides.
  • a compound may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronarily.
  • the compound is best used in the form of a sterile aqueous solution that may contain other substances, for example salts, or monosaccharides such as manni
  • the effective dose of the herbal drug composition may vary with the age, weight, physical condition and response of the particular patient and administration may be made once a day or a few times a day according to the physician.
  • Preferred dosages for an average adult patient are as follows: in the range of from 50 to 2400 mg daily for oral administration such as individual tablets or capsules; in the range of from 50 to 400 mg daily for parenteral administration; in the range of from 300 to 2400 mg daily for ointments; and in the range of from 150 to 1200 mg daily for transdermal administration.
  • the above dosages are exemplary of the average case but there can be individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention.
  • the daily dosages of the herbal drug composition are less than the above ranges, the desired effects are not obtained. On the other hands, if they are higher than the above ranges, it is also not preferable due to toxic side effects.
  • the toxic side effect is far less than other chemically synthesized drugs.
  • several toxicological tests reveal that the combined extract of the present invention is not toxic to the human.
  • Clematis Radix, Trichosanthis Radix, and Prunellae Spica having 1.5% (w/w) of rosmarinic acid, 3.5% (w/w) of oleanolic acid, and 0.02% (w/w) of 4-hydroxybenzoic acid were mixed and n-butanol fractionation was performed three times, respectively.
  • the extract obtained each step was combined and well suspended in the same amount of distilled water and lyophilized to give powdered extract.
  • Clematis Radix, Trichosanthis Radix, and Prunellae Spica having 0.7% (w/w) of rosmarinic acid, 5.0% (w/w) of oleanolic acid, and 0.01% (w/w) of 4-hydroxybenzoic acid were mixed and n-butanol fractionation was performed three times, respectively.
  • the extract obtained each step was combined and well suspended in the same amount of distilled water and lyophilized to give powdered extract.
  • Clematis Radix, Trichosanthis Radix, and Prunellae Spica having 4.0% (w/w) of rosmarinic acid, 2.0% (w/w) of oleanolic acid, and 0.04% (w/w) of 4-hydroxybenzoic acid were mixed and n-butanol fractionation was performed three times, respectively.
  • the extract obtained each step was combined and well suspended in the same amount of distilled water and lyophilized to give powdered extract.
  • the powdered extract was determined by HPLC analysis having 2.1% (w/w) of rosmarinic acid, 2.1% (w/w) of oleanolic acid, and 2.5% (w/w) of 4-hydroxybenzoic acid.
  • the powdered extract was determined by HPLC analysis having 0.4% (w/w) of rosmarinic acid, 6.8% (w/w) of oleanolic acid, and 0.05% (w/w) of 4-hydroxybenzoic acid.
  • Each extract of Clematis Radix, Trichosanthis Radix, and Prunellae Spica prepared in Reference Examples 1, 2, and 3 was mixed and dissolved in aqueous alcoholic solution to have the contents of 0.45% (w/w) of rosmarinic acid, 6.11% (w/w) of oleanolic acid, and 0.02% (w/w) of 4-hydroxybenzoic acid.
  • the mixture was concentrated under reduced pressure.
  • the extract was well suspended in the same amount of distilled water and lyophilized to give powdered extract.
  • the herbal extracts prepared by said Examples 1-4 and Comparative Examples 1-2, were orally administered to ICR (Institute of Cancer Research) mice at doses of 200 mg or 400 mg per Kg of body weight.
  • the herbal extracts prepared by said Examples 1-4 and Comparative Examples 1-2, was orally administered to white SD (Spraque-Dawley) rats. At one hour after administration, 0.1 ml of 1% carrageenan was intradermally injected to the left hind paw of rats and edema at that site was measured at 1 hour interval for 5 hours.
  • PRP platelet rich plasma
  • the herbal extracts prepared by said Examples 1-4 and Comparative Examples 1-2, were added to the PRP and adjusted on a cuvette of aggregometer at 37° C. for 2 minutes. With the addition of collagen platelet aggregation was measured with a dual aggregometer.
  • Hyaluronidase was prepared in the presence of acetate buffer solution at 37° C. for 20 minutes and activated. Then the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, and potassium hyaluonate as a substrate were added to the buffer solution and cultured for about 40 minutes. After terminating the reaction with sodium hydroxide, potassium borate was added to the cultures and heated at 100° C. The absorbance was measured by the development of DMBA (dimethylbenzanthracene) and the rate of inhibition was calculated in comparison with control. TABLE 5 Test Rate of concentration inhibition Category (mg/ml) (%) Example 1 1 82.3 Example 2 1 83.7 Example 3 1 89.6 Example 4 1 87.5 Comparative Example 1 1 80.5 Comparative Example 2 1 79.1
  • Cartilage from rabbits was dissected from each joint and 50 mg of cartilage was placed in a culture medium adjusted at 37° C.
  • the herbal extract, prepared by said Examples 1-4 and Comparative Examples 1-2, and 5 ⁇ g of interleukin-1 ⁇ (IL-1 ⁇ ) per 50 mg of cartilage were added to the culture medium and cultured for 72 hours.
  • the production of glucosaminoglycan (GAG) which is produced by proteoglycan degradation, was measured at 525 nm by coloring with 1,9-dimethylmethylene blue dye. TABLE 10 Test Rate of inhibition conc.
  • Example 1 1.0 115 0.3 83 0.1 68
  • Example 2 1.0 103 0.3 91 0.1 79
  • Example 3 1.0 99 0.3 81 0.1 73
  • Example 4 1.0 121 0.3 94 0.1 75 Comparative 1.0 84
  • Example 1 0.3 52 0.1 38 Comparative 1.0 81
  • Example 2 0.3 46 0.1 37
  • Cartilage from rabbits was dissected from each joint and 50 mg of cartilage was placed in a culture medium adjusted at 37° C.
  • the herbal extract, prepared by said Examples 1-4 and Comparative Examples 1-2, and 5 ⁇ g of interleukin-l ⁇ (IL-1 ⁇ ) per 50 mg of cartilage were added to the culture medium and cultured for 21 days.
  • the production of hydroxy proline, which is produced by type II collagen degradation, was measured at 560 nm by coloring with chloramines-T and dimethylaminobenzaldehyde. TABLE 11 Rate of inhibition on the proliferation Category Test conc.
  • Example 1 1.0 91 0.3 63 0.1 38
  • Example 2 1.0 89 0.3 59 0.1 39
  • Example 3 1.0 97 0.3 76 0.1 53
  • Example 4 1.0 93 0.3 65 0.1 46 Comparative 1.0 67
  • Example 1 0.3 36 0.1 19 Comparative 1.0 65
  • Example 2 0.3 36 0.1 20
  • Chemical Composition the herbal drug composition 200 mg; hard anhydrous silicate 10 mg; Magnesium stearate 2 mg; microcrystalline cellulose 50 mg; Sodium starch glycolate 25 mg; corn starch 113 mg; and anhydrous ethanol in an appropriate amount.
  • composition the herbal drug composition 5 g; cetyl palmitate 20 g; cetyl alcohol 40 g; stearyl alcohol 20 g; isopropyl myristate 80 g; sorbitan monostearate 20 g; polysorbate 60 g; propyl p-hydroxybenzoate 1 g; methyl p-hydroxybenzoate 1 g; and phosphoric acid and distilled water in an appropriate amount.
  • Chemical Composition the herbal drug composition 100 mg; mannitol 180 mg; Na 2 HPO 4 25 mg; and water for injection 2,974 mg.
  • Chemical Composition 1 the herbal drug composition 0.4 g; poly(acrylic acid, sodium salt) 1.3 g; glycerin 3.6 g; aluminum hydroxide 0.04 g; methyl paraben 0.2 g; and water 14 g.
  • Chemical Composition 2 the herbal drug composition 0.8 g; propylene glycol 1.6 g; fluid paraffin 0.8 g;
  • dosage forms e.g., tablets, ointments, transdermal and injection solutions
  • Said preparations contain concentrations of oleanolic acid and rosmarinic acid as reference materials, thus being effectively used for anti-inflammatory agent with analgesic effects, chronic rheumatoid arthritis drug and agent for improving peripheral blood circulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a herbal drug composition for cartilage protection comprising plant extracts of Clematis Radix, Trichosanthis Radix, and Prunellae Spica and an optimal content of rosmarinic acid to: (i) alleviate pains; (ii) inhibit the acute/chronic inflammation, platelet/whole blood aggregation, immunocyte (B-lymphcyte and T-lymphcyte) proliferation, inflammation-inducing enzyme activities, and enzyme activities associated with degradation of joint tissue; (iii) scavenge activity of toxic active oxygen radicals; and (iv) further provide excellent cartilage protection activity to be effectively used as an anti-inflammatory agent with analgesic effects, blood circulation enhancer, arthritis therapeutic agent and cartilage protective.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a herbal drug composition for cartilage protection and more particularly, to the drug composition for cartilage protection comprising plant extracts of Clematis Radix, Trichosanthis Radix, and Prunellae Spica and an optimal content of rosmarinic acid to: (i) alleviate pains; (ii) inhibit the acute/chronic inflammation, platelet/whole blood aggregation, immunocyte (B-lymphocyte and T-lymphocyte) proliferation, inflammation-inducing enzyme activities, and enzyme activities associated with degradation of joint tissue; (iii) scavenge activity of toxic active oxygen radicals; and (iv) further provide excellent cartilage protection activity to be effectively used as an anti-inflammatory agent with analgesic effects, blood circulation enhancer, arthritis therapeutic agent and cartilage protective. [0001]
    • BACKGROUND OF THE INVENTION
  • Clematis Radix, Trichosanthis Radix, and Prunellae Spica are well known for medicinal plants. Each medicinal plant has long been used for the treatment of general inflammations, such as various swellings, wounds, bronchitis, mastitis, tonsillitis, and anal fistula and also for the relief of various symptoms such as cold or numb hands, painful knees, painful waist and shoulder, feeble in health and pain in the skin, in the form of aqueous plant extract. These symptoms are similar to general arthritis including chronic rheumatism in terms of the modern pathological concept. Clematis Radix, a root of [0002] Clematis mandshurica and the same genera in plant taxonomy, is distributed in the shady forest throughout Asia. It is collected in autumn, washed cleanly after removing cormophyte and root hair, chopped finely and dried in the sun to be used as a medicinal use. Clematis Radix, a non-toxic medicinal plant, has long been used for the treatment of the following symptoms: pains in the extremities; motor disturbance in knee joints; and paralysis in the extremities. In particular, Clematis Radix has been frequently used as a miraculous drug in those patients who feel uncomfortable while standing due to the coldness in waist, knees and feet. It is well known that Clematis Radix has various constituents of flavanone glycosides such as clematin, etc. and saponins such as clemontanoside A, clemontanoside B, clemontanoside C, and clemontanoside S, glucoses, and sterols [Research Archives of Useful Plants Resources in Korea, Korea Research Institute of Chemical Technology, pp780-781(1988), 2. An Explanatory Diagram of Korean Medicinal plants, Youngrim Pub., pp489-490(1990)].
  • Trichosanthis Radix, known as “multifarious medicine” or “Karokon”, is a non-toxic medicinal herb prepared by collecting roots of [0003] Trichosnathes kirilowii and the same genera in plant taxonomy, which are perennial liana plants, in autumn. The outer shells of cleanly washed roots are removed and the rest of the roots are cut appropriately and dried in the sun for medicinal use. Trichosanthis Radix has been widely used for excretion of pus, vanishing the boil, detoxification and antipyretic effect and also effective for diseases symptomized by thirst, various swellings, mastitis, and anal fistula. It has been investigated up to now that Trichosanthis Radix contains trichosanthin as proteins, arginine and citruline as amino acids, and palmitic acid and linoleic acid as fatty acids. Recently Trichosanthis Radix is found to contain bryonolic acid, 4-hydroxybenzoic acid, α-spinastero as sterols [Research Archives of Useful Plants Resources in Korea, Korea Research Institute of Chemical Technology, pp 354-357(1988), 2. An Explanatory Diagram of Korean Medicinal Plants, Youngrim Pub., pp960-963(1990)].
  • Prunellae Spica, a flower or upper part of [0004] Prunella vulgaris and the same genera in plant taxonomy, is a non-toxic medicinal herb prepared by collecting the flower, when it is half withered during summer, and drying in the sun. Prunellae Spica has been widely used for the treatment of the following symptoms: chronic swellings, smallpox, acute mastitis and lymphatic tuberculosis. Prunellae Spica is also effective in the destructing lumps (generated in a lower stomach owing to extravasated blood) or others, while treating beriberi and numbness in the extremities. It has been reported that Prunellae Spica contains saponins such as oleanolic acid glycosides and ursolic acid glycosides, etc, and also contains carotene, vitamin C, vitamin K, tannin, caffeic acid and chlorogenic acid. Rosmarinic acid is also found in Prunellae Spica [Research Archives of Useful Plant Resources in Korea, Korea Research institute of Chemical Technology, pp 480-482(1988); Chemical Research for Prunellae Spica, Lee Jak-pyung et al., Bulletin of Medical College in Beijing, 17(4), pp297-299(1985); Pharm. Acta. Helv., 66, No. 7, pp185-188(1991)].
  • The conventional oriental herbal books (e.g., Dong-Eui-Bo-gam, Hyangyak Gibsung-bang and Kwangjee Beakub) or related literatures refer to the medical efficacy of herbs and processes of manufacturing aqueous herbal solutions. However, they only described a single prescription of each of these medicinal plants but not a formulation available for the manufacture of aqueous herbal solution from appropriate combinations of sorted medicinal plants by harvest place and harvest time to control the content of active ingredients. Furthermore, these medicinal plants were prepared by hot water extraction method, and any substances extracted by above method showed no acquisition of detailed knowledge on biologically active ingredients. [0005]
  • On the other hand, the inventors of the present invention have disclosed a process of extraction and purified biologically effective ingredients from an extract of Clematis Radix, Trichosanthis Radix, and Prunellae Spica in a certain ratio, being useful for alleviating acute/chronic inflammation; for inhibiting platelet and whole blood aggregation, enzyme activities associated with degradation of joint tissue, abnormally proliferated immunocytes, and inflammation-inducing enzymes; for scavenging activity of toxic active oxygen radical; and further for the treatment of chronic rheumatoid arthritis (U.S. Pat. No. 5,910,307). U.S. Pat. No. 5,910,307 is characterized by mixing Clematis Radix, Trichosanthis Radix, and Prunellae Spica in a weight ratio of 1:0.5-2:0.5-1.5 and extracting the mixture with water or aqueous alcoholic solution; partitioning with water-saturated n-butanol and concentrating the alcohol layer under reduced pressure; and concentrating the result with water under constant boiling and lyophilizing to obtain an extract in powder form. [0006]
  • In the continuous study, the inventors have realized that it is difficult to standardize the extracts of Clematis Radix, Trichosanthis Radix, and Prunellae Spica with simple weight ratio since the content variation of each ingredient significantly varies with harvest place and harvest time. This further makes it difficult to merchandize such combined extracts since it is hard to obtain the reproducibility of active ingredients having analgesic and anti-inflammatory effects, blood circulation enhancing effect, arthritis therapeutic effect and cartilage protection. Thereupon, the inventors have made an extensive research to maximize the pharmacological efficiency of herbal drug composition with the reproducibility. As a result, we have developed a method to optimize the efficiency of cartilage protection effect as well as the analgesic and anti-inflammatory effect, blood circulation enhancing effect, and arthritis therapeutic effect by controlling the content of rosmarinic acid in the herbal drug composition, not the extract weight ratio of Clematis Radix, Trichosanthis Radix, and Prunellae Spica. In addition, it was possible to merchandize medicinal herbs with the reproducibility. [0007]
  • The present invention, an improved invention of U.S. Pat. No. 5,910,307, provides significant improvement in merchandizing by optimizing the herbal extract composition of Clematis Radix, Trichosanthis Radix, and Prunellae Spica with the proper content of rosmarinic acid, maximizes pharmacological efficiencies over the conventional herbal composition and further provides novel therapeutic effects. [0008]
    • SUMMARY OF THE INVENTION
  • The present invention is to provide a herbal drug composition comprising Clematis Radix, Trichosanthis Radix, and Prunellae, wherein the ingredients extracted and purified are standardized and merchandized based on the content of rosmarinic acid for the purpose of reproducibility and useful for an anti-inflammatory agent with analgesic effects, blood circulation enhancer, arthritis therapeutic agent and cartilage protective, etc. The herbal drug composition of the present invention has similar or superior efficiency for analgesic and anti-inflammatory effect and improving blood circulation to the conventional herbal composition of U.S. Pat. No. 5,910,307. In addition to that, it has excellent inhibitory activities against enzymes associated with degradation of joint tissue and a protection activity toward cartilage and thus, it is superiorly effective to general arthritis including rheumatism. [0009]
  • Accordingly, the object of the present invention is to provide a herbal drug composition having excellent analgesic and anti-inflammatory effect, improving effect of peripheral blood circulation, arthritis therapeutic effect and cartilage protection effect by standardizing the extracts from mixed Clematis Radix, Trichosanthis Radix, and Prunellae Spica with the proper content of rosmarinic acid.[0010]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 represents the inhibitory activity of the herbal drug composition on edema induced by carrageenan. [0011]
  • FIG. 2 represents the anti-coagulant activity of the herbal drug composition on platelet aggregation. [0012]
  • FIG. 3 represents the anti-coagulant activity of the herbal drug composition on whole blood aggregation. [0013]
  • FIG. 4 represents the inhibitory activity of the herbal drug composition on chronic inflammation. [0014]
  • FIG. 5 represents the inhibitory activity of the herbal drug composition on B-lymphocyte proliferation. [0015]
  • FIG. 6 represents the inhibitory activity of the herbal drug composition on T-lymphocyte proliferation.[0016]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is characterized by a combined herbal drug composition comprising Clematis Radix, Trichosanthis Radix, Prunellae Spica and more than 0.6 wt. % of rosmarinic acid based on the total composition. [0017]
  • The present invention is described in detail as set forth hereunder. [0018]
  • The herbal drug composition of the present invention provides significant biological effects such as analgesic and anti-inflammations, improvement of blood circulation, immunoregulation and inhibitions on enzymes associated with degradation of joint tissue, and particularly, cartilage protection and thus, being useful as arthritis therapeutic agent and cartilage protective as well as an analgesic and anti-inflammatory agent and blood circulation enhancer. [0019]
  • The content of active ingredients in herbal drugs varies remarkably with harvest place, harvest time, storage period and storage condition. Therefore, it is desirable to combine herbal extracts or herbal plants in an appropriate ratio depending on the harvest place as shown in Tables 1 to 3. That is, if harvest place, harvest time, storage period and storage condition are different, the content of active ingredients contained in the same weight of herbal plant has different contents, thus the limitation with the weight ratio of herbal extracts or herbal plants becomes insignificant. [0020]
  • Therefore, the present invention is characterized by selecting rosmarinic acid as a reference material to obtain the herbal drug composition with optimal pharmacological efficiency. Rosmarinic acid is known to have excellent activities such as: (i) antioxidant activity by inhibiting lipid peroxidation and/or biosynthesis of prostacyclin generated in the metabolism of arachidonic acid, and by scavenging the active oxygen generated from polymorphonuclear leukocytes; (ii) anti-inflammatory activity such as inhibition against the generation of metabolites which are carriers for inflammation reaction and immunoregulation to inhibit allergic inflammation; (iii) blood circulation enhancing activity by inhibition of platelet blood aggregation and fiber degradation [[0021] Agent and Action, 17, pp375-376(1985); Pharm. Acta. Helv., 66, No. 7, pp185-188(1991); Biochem. Pharmae., 29, pp533-538(1980); Yoa-Hsueh-Hseuh-Pao, 27, pp96-100(1992); Int. J. of Immunopharmae., 10, No. 6, pp729-737(1988); J. of Natural Products, 50, No. 3, pp392-399(1987); Yoa-Hsueh-Hseuh-Pao, 28, No. 4, pp241-245(1993)]. The variation of a rosmarinic acid content is broad depending on harvest place, harvest time, storage period and storage condition etc. and further the efficiency varies with the content of rosmarinic acid. This is the reason why rosmarinic acid is selected as a reference material in the present invention. Accordingly, the herbal drug composition of the present invention can be prepared by mixing the herbal extracts of Clematis Radix, Trichosanthis Radix, Prunellae Spica or extracting the mixture of Clematis Radix, Trichosanthis Radix, Prunellae Spica not depending on the weight ratio of each herbal plant but depending on the content of rosmarinic acid contained in the total herbal plants.
  • The herbal drug composition can obtain the desired pharmaceutical efficiencies when the content of rosmarinic acid is higher than 0.6 wt. % of rosmarinic acid, preferably 0.6-5.0 wt. %. When the content of rosmarinic acid is higher than 0.6 wt. % in the herbal drug composition comprising Clematis Radix, Trichosanthis Radix, Prunellae Spica, it provides optimal effects such as cartilage protection activity which has not been taught in the conventional herbal drug compositions as well as alleviation of pains, improvement of blood circulation, immunoregulation, and inhibition of enzymes associated with degradation of joint tissue. If the content of rosmarinic acid is lower than 0.6 wt. %, the herbal drug composition provides alleviation of pains, improvement of blood circulation, immunoregulation, and inhibition of enzymes associated with degradation of joint tissue but very sluggish cartilage protection activity. The present invention has no upper limitation for the amount of the rosmarinic acid but when it is higher than a certain level, the activities are not improved any further, thus it is not desirable technically and economically to increase the content of rosmarinic acid to higher than a certain level. [0022]
  • According to the present invention, when the herbal drug composition contains 2.0-6.0 wt. % of oleanolic acid and 0.01-0.04 wt. % of 4-hydroxybenzoic acid in addition to higher than 0.6 wt. % of rosmarinic acid, it provides far more potent efficacy toward cartilage protection activity as well as alleviation of pains, improvement of blood circulation, immunoregulation, and inhibition of enzymes associated with degradation of joint tissue. [0023]
  • Large quantity of oleanolic acid is present in the extract of Clematis Radix. When the extract is hydrolyzed, sufficient amounts of oleanolic acid are present as a sapogenin, a sugar-free form of saponins. According to an analysis, it is found that oleanolic acid is present as saponins bonded to various glycosides. It has been reported that oleanolic acid has not only remarkable anti-inflammatory and analgesic effects but also an excellent effect for chronic rheumatoid arthritis induced by [0024] Mycobacterium butyricum [J. of Pharm. Pharmacol., 44, No.5, pp456-458(1992); Chung-Kuo-Li-Hsueh-Pao, 10, No.4, pp381-384(1984); Chem. Pharm, Bull., 28, No.4, pp1183-1188(1980); Biochem. Int., 24, No.5, pp981-990(1991)].
  • The extract of Trichosanthis Radix contains various organic acids including 4-hydroxybenzoic acid. 4-hydroxybenzoic acid is known to have excellent anti-oxidant activity, anti-inflammatory activity and hormone-like effect in the uterus ablation osteoporotic model and further is one of reference materials for the present invention because it is maintained in a certain amount regardless of harvest place, harvest time, storage period and storage conditions [[0025] Free Radical Biol. & Medcine, 27, No.11/12, pp1427-1436(1999); J. Ethnopharma., 53, 11-14(1996); Environ. Res., 75, pp130-134(1997)].
  • Rosmarinic acid, oleanolic acid and 4-hydroxybenzoic acid selected as reference materials are active ingredients of herbal drug composition obtained from this invention. The efficacy is far more potent due to remarkable synergic effect when they are combined in a certain ratio based on the contents of active ingredients. Further, in addition to such active ingredients of the herbal drug composition from this invention, other different ingredients cannot be ruled out in this invention. [0026]
  • To contain certain amounts of reference materials, the herbal drug composition of the present invention is prepared by either mixing each extract in powder form of Clematis Radix, Trichosanthis Radix, and Prunellae or extracting the mixture of Clematis Radix, Trichosanthis Radix, and Prunellae Spica based on the chemical analysis of original herbal plants. The method for preparing herbal drug composition makes a little difference in cartilage protection activity. The method for preparing herbal drug composition is described in detail as set forth hereunder. [0027]
  • Each Clematis Radix, Trichosanthis Radix, and Prunellae Spica or a mixture thereof is extracted with 5-10 volumes of water or aqueous alcoholic solution under reflux for 4 to 6 hours and filtered. The filtrate is further extracted with 5-10 volumes of water or aqueous alcoholic solution under reflux and filtered. Each extract is combined and concentrated to dryness. Hence, if a small amount of the solvent is used, the extraction efficiency is low due to the lower solubility of extract and the difficulty of stirring the extract. In case of using an excess of the solvent, however, a larger amount of solvent saturated with lower alcohol in water has to be evaporated and removed, therefore which is uneconomical and difficult in handling. The present invention performs a series of extraction steps, i.e., first and second extraction, because when the extraction is on a large scale, significant losses are anticipated due to high contents of water in medicinal plants, in spite of effective filtration. So the second extraction is responsible for preventing the reduced extraction efficiency rather than the first extraction only. Further, it is revealed that about 85-95% of the total extract amount is obtained through two extractions. It is also found that more than three steps of extraction are not to be desirable in economical matter. [0028]
  • The extracts are filtered and concentrated, and the filtrate is purified to remove some impurities such as proteins, polysaccharides and fatty acids by extracting with the same amount of lower alcohol saturated with 3-4 volumes of water. Examples of lower alcohol used in the present invention include butyl alcohol and propyl alcohol. If the amount of water-saturated lower alcohol is less than that of the filtrate, a higher concentration of impurities (e.g., polysaccharides, and proteins) having relatively strong polarity causes lower concentration of active ingredients in the extracts due to poor separation of layers. [0029]
  • After separating the layers, the obtained fractions extracted with alcohol are concentrated under reduced pressure at 60-70° C. to remove lower alcohol in the sample. Then, the extract is further concentrated 2-3 times under constant boiling with 25-50 volumes of water to the total extract amount and followed with another same amount of water for homogeneous suspension. The reason why the residue is concentrated under constant boiling with water is to control the contents of remaining lower alcohol so as to use the extracting solution as pharmaceutical raw materials. The obtained extract is then lyophilized to give an extract powder. [0030]
  • The obtained extract powder has significant pharmacological effects, such as analgesic and anti-inflammatory agents, blood circulation enhancers, rheumatoid arthritis therapeutic agents, and cartilage protection agents. [0031]
  • Based on the general manufacturing method, the powdered extract of this invention is formulated in oral or parenteral administration such as tablets, soft gelatin capsules, injection solutions, ointments, and transdermals. [0032]
  • For human use, the herbal drug composition of this invention can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, the herbal drug composition may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. Such liquid preparations may be prepared with pharmaceutically acceptable additives such as suspending agent (e.g., methylcellulose, a semi-synthetic glyceride such as witepsol or mixtures of glycerides such as a mixture of apricot kernel oil and PEG-6 esters or mixtures of PEG-8 and caprylic/capric glycerides). A compound may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronarily. For parenteral administration, the compound is best used in the form of a sterile aqueous solution that may contain other substances, for example salts, or monosaccharides such as mannitol or glucose, to make the solution isotonic with blood. [0033]
  • For administration to man, the effective dose of the herbal drug composition may vary with the age, weight, physical condition and response of the particular patient and administration may be made once a day or a few times a day according to the physician. Preferred dosages for an average adult patient (70 Kg) are as follows: in the range of from 50 to 2400 mg daily for oral administration such as individual tablets or capsules; in the range of from 50 to 400 mg daily for parenteral administration; in the range of from 300 to 2400 mg daily for ointments; and in the range of from 150 to 1200 mg daily for transdermal administration. The above dosages are exemplary of the average case but there can be individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention. Further, if the daily dosages of the herbal drug composition are less than the above ranges, the desired effects are not obtained. On the other hands, if they are higher than the above ranges, it is also not preferable due to toxic side effects. [0034]
  • In particular, while the herbal drug composition of the present invention was administered to human, the toxic side effect is far less than other chemically synthesized drugs. As a matter of fact, several toxicological tests reveal that the combined extract of the present invention is not toxic to the human. [0035]
  • The present invention is explained in more detail with reference to the following examples that should not be taken to limit the scope of the invention. [0036]
    • REFERENCE EXAMPLE 1
  • 250 g of well air dried Clematis Radix where debris were removed by washing with water was extracted from 2 l of 30% (v/v) ethanol-containing water under reflux for 6 hrs while stirring. After filtration, the residue was extracted again from 1.5 l of 30% (v/v) ethanol-containing water under reflux for 6 hrs while stirring. The filtrates were combined and concentrated to have 1 l of the total volume. The filtrate was extracted with a same volume of water-saturated n-butanol three times. The n-butanol layers were combined and concentrated under reduced pressure at 60-70° C. to dryness. 0.3 l of water was added to the residue and extracted under constant boiling and repeated the procedure twice. The extract was well suspended in the same amount of distilled water and lyophilized to give powdered extract. [0037]
  • Other Clematis Radix harvested in different places were prepared by the above procedure and analyzed by high performance liquid chromatography. The result was summarized in Table 1 with the content (%) of oleanolic acid. [0038]
    TABLE 1
    Harvest Content of Yield
    place (China) oleanolic acid (%) (%, w/w)
    Heilongjiang A 6.98 3.25
    Heilongjiang B 13.59 3.95
    Heilongjiang C 2.68 2.76
    Jilin A 9.29 2.58
    Jilin B 0.12 4.05
    Jilin C 8.96 2.94
    Liaoning A 8.53 3.08
    Liaoning B 6.75 2.83
    Liaoning C 3.97 1.79
    Sichuan A 0.15 3.64
    Sichuan B 6.98 2.36
    • REFERENCE EXAMPLE 2
  • [0039] 250 g of well air dried Trichosanthis Radix where debris were removed by washing with water was extracted from 2.5 l of 30% (v/v) ethanol-containing water under reflux for 4 hrs while stirring. After filtration, the residue was extracted again from 1.5 l of water under reflux for 3 hrs while stirring. The filtrates were combined and concentrated to have 1 l of the total volume. The filtrate was extracted with a same volume of water-saturated n-butanol three times. The n-butanol layers were combined and concentrated under reduced pressure at 60-70° C. to dryness. 0.2 l of water was added to the residue and extracted under constant boiling and repeated the procedure twice. The extract was well suspended in the same amount of distilled water and lyophilized to give powdered extract.
  • Other Trichosanthis Radix harvested in different places were prepared by the above procedure and analyzed by high performance liquid chromatography. The result was summarized in Table 2 with the content (%) of rosmarinic acid. [0040]
    TABLE 2
    Harvest Content of Yield
    place (China) rosmarinic acid (%) (%, w/w)
    Henan A 3.13 2.17
    Henan B 12.05 2.28
    Henan C 8.34 2.06
    Hubei A 1.89 2.40
    Hubei B 7.22 3.20
    Hubei C 5.75 1.52
    Hunan A 10.96 2.74
    Hunan B 4.89 1.92
    Hunan C 13.00 3.19
    Sichuan A 6.14 1.32
    Sichuan B 12.45 1.40
    Sichuan C 1.59 2.82
    • REFERENCE EXAMPLE 3
  • [0041] 250 g of well air dried Prunellae Spica having a length of 2.0-4.0 cm where debris were removed by washing with water was extracted from 2 l of water under reflux for 5 hrs while stirring. After filtration; the residue was extracted again from 2 l of water under reflux for 3 hrs while stirring. The filtrates were combined and concentrated to have 1 l of the total volume. The filtrate was extracted with a same volume of water-saturated n-butanol three times. The n-butanol layers were combined and concentrated under reduced pressure at 60-70° C. to dryness. 0.1 l of water was added to the residue and extracted under constant boiling and repeated the procedure twice. The extract was well suspended in the same amount of distilled water and lyophilized to give powdered extract.
  • Other Trichosanthis Radix harvested in different places were prepared by the above procedure and analyzed by high performance liquid chromatography. The result was summarized in Table 3 with the content (%) of 4-hydroxybenzoic acid. [0042]
    TABLE 3
    Harvest Content of
    place 4-hydroxybenzoic Yield
    (China) acid (%) (%, w/w)
    Hebei A 0.018 0.95
    Hebei B 0.024 0.76
    Hebei C 0.037 0.82
    Henan A 0.047 0.91
    Henan B 0.058 1.05
    Henan C 0.019 0.064
    Anhui A 0.041 0.71
    Anhui B 0.058 1.23
    Anhui C 0.098 0.86
    Zhejiang A 0.045 0.79
    Zhejiang B 0.073 1.08
    Zhejiang C 0.062 1.19
    • EXAMPLE 1 Preparation of a Mixture of the Herbal Drug Extracts
  • Clematis Radix, Trichosanthis Radix, and Prunellae Spica having 1.5% (w/w) of rosmarinic acid, 3.5% (w/w) of oleanolic acid, and 0.02% (w/w) of 4-hydroxybenzoic acid were mixed and n-butanol fractionation was performed three times, respectively. The extract obtained each step was combined and well suspended in the same amount of distilled water and lyophilized to give powdered extract. [0043]
    • EXAMPLE 2 Preparation of a Mixture of the Herbal Drug Extracts
  • Clematis Radix, Trichosanthis Radix, and Prunellae Spica having 0.7% (w/w) of rosmarinic acid, 5.0% (w/w) of oleanolic acid, and 0.01% (w/w) of 4-hydroxybenzoic acid were mixed and n-butanol fractionation was performed three times, respectively. The extract obtained each step was combined and well suspended in the same amount of distilled water and lyophilized to give powdered extract. [0044]
    • EXAMPLE 3 Preparation of a Mixture of the Herbal Drug Extracts
  • Clematis Radix, Trichosanthis Radix, and Prunellae Spica having 4.0% (w/w) of rosmarinic acid, 2.0% (w/w) of oleanolic acid, and 0.04% (w/w) of 4-hydroxybenzoic acid were mixed and n-butanol fractionation was performed three times, respectively. The extract obtained each step was combined and well suspended in the same amount of distilled water and lyophilized to give powdered extract. [0045]
    • EXAMPLE 4 Preparation of a Herbal Extract of Mixed Plants
  • 200 g of well dried Clematis Radix harvested in Heilongjiang A where debris were removed by washing with water, 450 g of Trichosanthis Radix harvested in Henan A with a length of 2.0-4.0 cm, and 350 g of Prunellae Spica harvested in Henan B were mixed and the mixture was extracted with 10 l of water under reflux for 6 hrs. After filtration, the residue was extracted again from 7 l of water under reflux for 3 hrs while stirring. The filtrates were combined and concentrated to give 5 l of the total volume. The filtrate was extracted with the same volume of water-saturated n-butanol three times. The n-butanol layers were combined and concentrated under reduced pressure at 60-70° C. to dryness. One liter of water was added to the residue and extracted under constant boiling and repeated the procedure twice. The extract was well suspended in the same amount of distilled water and lyophilized to give powdered extract. [0046]
  • The powdered extract was determined by HPLC analysis having 2.1% (w/w) of rosmarinic acid, 2.1% (w/w) of oleanolic acid, and 2.5% (w/w) of 4-hydroxybenzoic acid. [0047]
    • COMPARATIVE EXAMPLE 1
  • Well dried Clematis Radix harvested in Heilongjiang B where debris were removed by washing with water, 500 g of Trichosanthis Radix harvested in Anhui C with a length of 2.0-4.0 cm, and 250 g of Prunellae Spica harvested in Hubei A were mixed and the mixture was extracted with 15 l of water under reflux for 6 hrs. After filtration, the residue was extracted again with 7 l of water under reflux for 3 hrs while stirring. The filtrates were combined and concentrated to give 5 l of the total volume. The filtrate was fractionated with the same volume of water-saturated n-butanol three times. The n-butanol layers were combined and concentrated under reduced pressure at 60-70° C. to dryness. One liter of water was added to the residue and extracted under constant boiling and the procedure was repeated twice. The extract was well suspended in the same amount of distilled water and lyophilized to give powdered extract. [0048]
  • The powdered extract was determined by HPLC analysis having 0.4% (w/w) of rosmarinic acid, 6.8% (w/w) of oleanolic acid, and 0.05% (w/w) of 4-hydroxybenzoic acid. [0049]
    • COMPARATIVE EXAMPLE 2 Preparation of a Mixture of Herbal Drug Extract
  • Each extract of Clematis Radix, Trichosanthis Radix, and Prunellae Spica prepared in Reference Examples 1, 2, and 3 was mixed and dissolved in aqueous alcoholic solution to have the contents of 0.45% (w/w) of rosmarinic acid, 6.11% (w/w) of oleanolic acid, and 0.02% (w/w) of 4-hydroxybenzoic acid. The mixture was concentrated under reduced pressure. The extract was well suspended in the same amount of distilled water and lyophilized to give powdered extract. [0050]
    • EXPERIMENTAL EXAMPLE 1 Test for Analgesic Effects
  • To investigate the analgesic effects of various extracts prepared by said Examples 1-4 and Comparative Examples 1-2, writhing test was conducted as presented in the following experimental method and the result was expressed as Table 4. [0051]
  • Experimental Method: [0052]
  • The herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, were orally administered to ICR (Institute of Cancer Research) mice at doses of 200 mg or 400 mg per Kg of body weight. [0053]
  • One hour after administration, 0.6% (v/v) acetic acid was intraperitoneally injected to the animals at a volume of 0.1 ml per 10 g of body weight and from 5 minutes after administration, writhing frequency of each mice was observed for 10 minutes as a pain threshold. [0054]
    TABLE 4
    Dose of herbal Avg. Rate of
    drug extract writhing inhibition
    Category (mg/Kg) frequency (%)
    Control — 19 —
    Example 1 200 12 36.8
    400 9 52.6
    Example 2 200 11 42.1
    400 8 57.9
    Example 3 200 11 42.1
    400 9 52.6
    Example 4 200 10 47.4
    400 7 63.2
    Comparative 200 13 31.6
    Example 1 400 10 47.4
    Comparative 200 14 26.3
    Example 2 400 11 42.1
  • According to the Table 4, it is revealed that the extract prepared by the present invention has superior analgesic effects from reduced writhing frequencies. [0055]
    • EXPERIMENTAL EXAMPLE 2 Test for Inhibitory Activity on Acute Inflammation
  • The inhibitory activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, on acute inflammation was investigated in rats. In comparison with the control, the anti-inflammatory effect on hind paw in edema was expressed as percent and the result is presented in the attached FIG. 1. [0056]
  • Experimental Method: [0057]
  • The herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, was orally administered to white SD (Spraque-Dawley) rats. At one hour after administration, 0.1 ml of 1% carrageenan was intradermally injected to the left hind paw of rats and edema at that site was measured at 1 hour interval for 5 hours. [0058]
  • As noted in the attached in FIG. 1, it is revealed that the herbal extracts prepared by said Examples 1-4 of the present invention significantly inhibited the carrageenan-induced inflammation. [0059]
    • EXPERIMENTAL EXAMPLE 3 Test for the Anti-Aggregating Activity
  • The anti-coagulant activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, was investigated in rabbits plasma and the aggregation was induced by collagen and the result is presented in the attached FIG. 2. [0060]
  • Experimental Method: [0061]
  • PRP (platelet rich plasma) was prepared from the blood sample of rabbits and the number of platelet in blood was adjusted at 2×10[0062] 8/ml. The herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, were added to the PRP and adjusted on a cuvette of aggregometer at 37° C. for 2 minutes. With the addition of collagen platelet aggregation was measured with a dual aggregometer.
  • As noted in the attached FIG. 2, there was no increase in platelet aggregation by the herbal. [0063]
    • EXPERIMENTAL EXAMPLE 4 Test for the Anti-Coagulant Activity on Whole Blood Coagulation
  • The anti-coagulant activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, was investigated using whole blood of rabbit and the result is presented in the attached FIG. 3. [0064]
  • Experimental Method: [0065]
  • The same amount of saline solution was added to whole blood of rabbit and mixed well prior to use in this experiment. The herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, were added to reconstituted whole blood and prewormed for 2 minutes. And, the blood coagulation was induced by the addition of collagen. The whole blood coagulation was measured by an aggregometer. As noted in the attached FIG. 3, there was no increase in whole blood coagulation when the herbal extracts prepared by said Examples 1-4 of the present invention was added. [0066]
    • EXPERIMENTAL EXAMPLE 5 Test for the Inhibitory Activity on Hyaluronidase, an Enzyme Associated with Degradation of Joint Tissue
  • The inhibitory activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, on hyaluronidase, an enzyme associated with degradation of joint tissue, was investigated and the result is presented in the following Table 5. [0067]
  • Experimental Method: [0068]
  • Hyaluronidase was prepared in the presence of acetate buffer solution at 37° C. for 20 minutes and activated. Then the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, and potassium hyaluonate as a substrate were added to the buffer solution and cultured for about 40 minutes. After terminating the reaction with sodium hydroxide, potassium borate was added to the cultures and heated at 100° C. The absorbance was measured by the development of DMBA (dimethylbenzanthracene) and the rate of inhibition was calculated in comparison with control. [0069]
    TABLE 5
    Test Rate of
    concentration inhibition
    Category (mg/ml) (%)
    Example 1 1 82.3
    Example 2 1 83.7
    Example 3 1 89.6
    Example 4 1 87.5
    Comparative Example 1 1 80.5
    Comparative Example 2 1 79.1
  • As shown in Table 5, the combined herbal extracts prepared by the present invention significantly inhibited the activation of the enzyme associated with degradation of joint tissue. [0070]
    • EXPERIMENTAL EXAMPLE 6 Test for the Inhibitory Activity on Chronic Inflammation
  • The anti-inflammatory activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, on chronic rheumatoid arthritis was investigated in [0071] Mycobacterium butyricum injected rat models. The result is presented in the attached FIG. 4.
  • Experimental Method: [0072]
  • To induce chronic edema, [0073] Mycobacterium butyricum suspended in mineral oil and treated with heat was injected to the right hind paw of white rats at each dose of 0.05 ml. Then, the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, were orally administered to the rats once daily for 16 days, and the paw edema was measured with plethysmometer.
  • As shown in the attached FIG. 4, the combined herbal extracts by the present invention significantly inhibited the edema. [0074]
    • EXPERIMENTAL EXAMPLE 7 Test for the Inhibitory Activity on Leukotriene B4
  • The inhibitory activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, on 5-lipoxygenase was evaluated by the inhibition rate of leukotriene B[0075] 4 (LTB4) biosynthesis induced by arachidonic acid and calcium ionophore (A23187) and the result is presented in the Table 6.
  • Experimental Method: [0076]
  • The extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, were added to rat basophilic leukemia-1 (RBL-1) cells adjusted at 37° C. and reacted for 5 minutes. Then the reacting mixture was treated with 20 μg/ml A23187 and arachidonic acid for 15 minutes so as to induce the generation of LTB[0077] 4. The generated LTB4 was extracted with ethyl acetate and was subjected to HPLC.
    TABLE 6
    Test Rate of
    concentration inhibition
    Category (mg/ml) (%)
    Example 1 0.5 87.3
    Example 2 0.5 82.5
    Example 3 0.5 79.1
    Example 4 0.5 85.7
    Comparative Example 1 0.5 71.5
    Comparative Example 2 0.5 70.6
  • As shown in the Table 6, the combined herbal extracts prepared by the present invention significantly inhibited 5-lipoxygenase. [0078]
    • EXPERIMENTAL EXAMPLE 8 Test for the Inhibitory Activity on Cyclooxygenase-I
  • The inhibitory activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2 on cyclooxygenase-I was evaluated by arachidonic acid and the result is presented in the Table 7. [0079]
  • Experimental Method: [0080]
  • The extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, were added to cyclooxygenase-I adjusted at 37° C., and 100 μM arachidonic acid was added and reacted for 2 minutes, trichloroacetic acid (TCA) was added to the reacting mixture for terminating the reaction and absorbance was measured at 530 nm. [0081]
    TABLE 7
    Test Rate of
    concentration inhibition
    Category (mg/ml) (%)
    Example 1 0.5 61.8
    Example 2 0.5 62.5
    Example 3 0.5 59.8
    Example 4 0.5 67.3
    Comparative Example 1 0.5 51.5
    Comparative Example 2 0.5 49.1
  • As shown in the Table 7, the combined herbal extracts prepared by the present invention significantly inhibited cyclooxygenase-I. [0082]
    • EXPERIMENTAL EXAMPLE 9 Test for the Inhibitory Activity on Cyclooxygenase-II
  • The inhibitory activity of the extracts, prepared by said Examples 1-2 and 5 Comparative Examples 1-3, on cyclooxygenase-II was evaluated and the result is presented in the Table 8. [0083]
  • Experimental Method: [0084]
  • The extracts prepared by said Examples 1-2 and Comparative Examples 1-3, were added to cyclooxygenase-II and placed at a test tube adjusted at 27° C. After reaction with 500 mM arachidonic acid for 90 seconds, trichloroacetic acid (TCA) was added to the reaction mixture for terminating the reaction and absorbance was measured at 532 nm. [0085]
    TABLE 8
    Test Rate of
    concentration inhibition
    Category (mg/ml) (%)
    Example 1 0.5 72.5
    Example 2 0.5 69.8
    Example 3 0.5 65.7
    Example 4 0.5 77.5
    Comparative Example 1 0.5 61.5
    Comparative Example 2 0.5 58.8
  • As shown in the Table 8, it is noted that the combined plant extracts prepared by this invention significantly inhibited cyclooxygenase-II. [0086]
    • EXPERIMENTAL EXAMPLE 10 Test for the Inhibitory Activity on the Proliferation of B-Lymphocyte
  • The inhibitory activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2 on the proliferation of B-lymphocyte induced by lipopolysaccharide (LPS) was evaluated and the result is presented in the attached FIG. 5. [0087]
  • Experimental Method: [0088]
  • Cultures were set up with 10[0089] 6 B-lymphocyte/ml of medium at 37° C. The extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, were added to the cultures, and then the cultures were treated with 10 μg/ml of LPS for 24 hours. With the addition of 2 μCi Thymidine-3H expressed by tritium as radioactivity for 48 hours, cultures were quantified on liquid scintillation counter (LSC).
  • As shown in the attached FIG. 5, it is noted that the combined herbal extracts prepared by the present invention significantly inhibited the proliferation of B-lymphocyte. [0090]
    • EXPERIMENTAL EXAMPLE 11 Test for the Inhibitory Activity on the Proliferation of T-Lymphocyte
  • The inhibitory activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, on the proliferation of T-lymphocyte induced by concanavalin-A (Con-A) were investigated and the result is presented in the attached FIG. 6. [0091]
  • Experimental Method: [0092]
  • Cultures were set up with 10[0093] 6 T-lymphocyte/ml of medium at 37° C. The extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, were added to the cultures, which were treated with 3 μg/ml of concanavalin-A for 24 hours. With the addition of 2 μCi Thymidine-3H expressed by tritium as radioactivity for 48 hours, cultures were quantified on LSC.
  • As shown in the attached FIG. 6, it is noted that the combined herbal extracts prepared by the present invention significantly inhibited the proliferation of T-lymphocyte. [0094]
    • EXPERIMENTAL EXAMPLE 12 Test for the Scavenging Activity on Elimination of Superoxide Radicals
  • The scavenging activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, was assessed on the elimination of superoxide radicals generated from xanthine-xanthine oxidase and the result is presented in the Table 9. [0095]
  • Experimental Method: [0096]
  • Cytochrome-c (Cyt-c) and herbal extracts, prepared by Examples 1-4 and Comparative Examples 1-2, were added to xanthine oxidase adjusted at 37° C. so as to induce the generation of oxygen radicals by xanthine. The changes in color along with oxidation of cytochrome-c (Cyt-c) was measured by spectrophotometer at 540 nm and scavenging rate of oxygen radicals was also measured as slope. [0097]
    TABLE 9
    Test Rate of
    concentration inhibition
    Category (mg/ml) (%)
    Example 1 0.5 82.7
    Example 2 0.5 89.5
    Example 3 0.5 83.6
    Example 4 0.5 92.1
    Comparative Example 1 0.5 81.5
    Comparative Example 2 0.5 78.4
  • As shown in the Table 9, it is noted that the combined herbal extracts prepared by the present invention significantly scavenged active oxygen. [0098]
    • EXPERIMENTAL EXAMPLE 13 Test for the Inhibitory Activity on Proteoglycan Degradation
  • The inhibitory activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, on the Proteoglycan degradation which is an important element in cartilage tissue was investigated and the result is presented in the Table 10. [0099]
  • Experimental Method: [0100]
  • Cartilage from rabbits was dissected from each joint and 50 mg of cartilage was placed in a culture medium adjusted at 37° C. The herbal extract, prepared by said Examples 1-4 and Comparative Examples 1-2, and 5 μg of interleukin-1α (IL-1α) per 50 mg of cartilage were added to the culture medium and cultured for 72 hours. The production of glucosaminoglycan (GAG), which is produced by proteoglycan degradation, was measured at 525 nm by coloring with 1,9-dimethylmethylene blue dye. [0101]
    TABLE 10
    Test Rate of inhibition
    conc. on the proliferation of
    Category (mg/ml) glucosaminoglycan (%)
    Example 1 1.0 115
    0.3 83
    0.1 68
    Example 2 1.0 103
    0.3 91
    0.1 79
    Example 3 1.0 99
    0.3 81
    0.1 73
    Example 4 1.0 121
    0.3 94
    0.1 75
    Comparative 1.0 84
    Example 1 0.3 52
    0.1 38
    Comparative 1.0 81
    Example 2 0.3 46
    0.1 37
  • As shown in the Table 10, it is noted that the combined herbal extracts prepared by the present invention significantly inhibited the proteoglycan degradation activity. [0102]
    • EXPERIMENTAL EXAMPLE 14 Test for the Inhibitory Activity on Type II Collagen Degradation
  • The inhibitory activity of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, on the Type II collagen degradation which is an important element in articular cartilage tissue was investigated and the result is presented in the Table 11. [0103]
  • Experimental Method: [0104]
  • Cartilage from rabbits was dissected from each joint and 50 mg of cartilage was placed in a culture medium adjusted at 37° C. The herbal extract, prepared by said Examples 1-4 and Comparative Examples 1-2, and 5 μg of interleukin-lα (IL-1α) per 50 mg of cartilage were added to the culture medium and cultured for 21 days. The production of hydroxy proline, which is produced by type II collagen degradation, was measured at 560 nm by coloring with chloramines-T and dimethylaminobenzaldehyde. [0105]
    TABLE 11
    Rate of inhibition on the proliferation
    Category Test conc. (mg/ml) of hydroxy-Proline (%)
    Example 1 1.0 91
    0.3 63
    0.1 38
    Example 2 1.0 89
    0.3 59
    0.1 39
    Example 3 1.0 97
    0.3 76
    0.1 53
    Example 4 1.0 93
    0.3 65
    0.1 46
    Comparative 1.0 67
    Example 1 0.3 36
    0.1 19
    Comparative 1.0 65
    Example 2 0.3 36
    0.1 20
  • As shown in the Table 11, it is noted that the combined herbal extracts prepared by the present invention showed more significant inhibitory activity on the Type II collagen degradation than that of Comparative Example 1. [0106]
    • EXPERIMENTAL EXAMPLE 15 Test for the Therapeutic Efficacy Against Osteoarthritis
  • The activity on oateoarthritis of the herbal extracts, prepared by said Examples 1-4 and Comparative Examples 1-2, on cartilage protection was investigated by monitoring rabbit models of which cartilage was injured by injecting collagenase to cavum articular of rabbit to have similar symptoms to human osteoarthritis. The result is presented in the Table 12. [0107]
  • Experimental Method: [0108]
  • 1 mg of collagenase per 1 Kg of body weight was injected at the first and fourth days to the cavum articular of rabbit having 2.0-2.5 Kg of body weight to injure joint tissue and to have collagenase-induced arthritis. The extracts, prepared by said example 1-4 and comparative example 1-2, were given orally at a dose of 200 mg/Kg for 4 weeks. After 4 weeks of administration, the cartilage part was dissected and withdrawn from the rabbit and then dyed with sapranin-O. The dyed cartilage part was divided into cartilaginous tissue and synovial tissue and the degree of arthritis severity was recorded with the integer scale of 0-4 to quantify the levels: 0=normal; 1=slight; 2=moderate; 3=severe; and 4=maximum. [0109]
    TABLE 12
    Cartilaginous
    Category tissue1) Synovial tissue2) Total3)
    Control 11.8 10.8 21.6
    Example 1 6.0 6.5 12.5
    Example 2 6.2 7.2 13.4
    Example 3 6.3 7.1 13.4
    Example 4 5.0 6.0 11.0
    Comparative 8.6 8.2 16.8
    Example 1
    Comparative 8.7 8.0 16.7
    Example 2
  • As shown in the Table 12, it is noted that the combined herbal extracts prepared by the present invention showed more significant alleviation activity on collagenase-induced arthritis than that of Comparative Example 1. [0110]
    • MANUFACTURING EXAMPLE 1
  • The following chemical composition was employed for the manufacture of oral tablets using the powdered extracts of the present invention. [0111]
  • Chemical Composition: the herbal drug composition 200 mg; hard [0112] anhydrous silicate 10 mg; Magnesium stearate 2 mg; microcrystalline cellulose 50 mg; Sodium starch glycolate 25 mg; corn starch 113 mg; and anhydrous ethanol in an appropriate amount.
    • MANUFACTURING EXAMPLE 2
  • The following chemical composition was employed for the manufacture of ointments using the powdered extracts of the present invention. [0113]
  • Chemical Composition: the herbal drug composition 5 g; cetyl palmitate 20 g; cetyl alcohol 40 g; stearyl alcohol 20 g; isopropyl myristate 80 g; sorbitan monostearate 20 g; polysorbate 60 g; propyl p-hydroxybenzoate 1 g; methyl p-hydroxybenzoate 1 g; and phosphoric acid and distilled water in an appropriate amount. [0114]
    • MANUFACTURING EXAMPLE 3
  • The following chemical composition was employed for the manufacture of injection solutions using the powdered extracts of the present invention. [0115]
  • Chemical Composition: the [0116] herbal drug composition 100 mg; mannitol 180 mg; Na2HPO4 25 mg; and water for injection 2,974 mg.
    • MANUFACTURING EXAMPLE 4
  • The following chemical composition was employed for the manufacture of transdermal using the powdered extracts of the present invention. [0117]
  • Chemical Composition 1: the herbal drug composition 0.4 g; poly(acrylic acid, sodium salt) 1.3 g; glycerin 3.6 g; aluminum hydroxide 0.04 g; methyl paraben 0.2 g; and water 14 g. [0118]
  • Chemical Composition 2: the herbal drug composition 0.8 g; propylene glycol 1.6 g; fluid paraffin 0.8 g; [0119]
  • Several dosage forms (e.g., tablets, ointments, transdermal and injection solutions) prepared by said manufacture 1-4 related to combined herbal preparations using Clematis Radix, Trichosabthis Radix and Prunellae Spica according to this invention. Said preparations contain concentrations of oleanolic acid and rosmarinic acid as reference materials, thus being effectively used for anti-inflammatory agent with analgesic effects, chronic rheumatoid arthritis drug and agent for improving peripheral blood circulation. [0120]

Claims (8)

What is claimed is:
1. A herbal drug composition for the cartilage protection comprising Clematis Radix, Trichosanthis Radix, Prunellae Spica, wherein more than 0.6 wt. % of rosmarinic acid is present in the total composition.
2. The herbal drug composition for the cartilage protection according to claim 1, wherein said rosmarinic acid is present in the range of from 0.6 to 5.0 wt. % relative to the total composition.
3. The herbal drug composition for the cartilage protection according to claim 1, wherein said herbal drug composition comprises oleanolic acid and 4-hydroxybenzoic acid in addition to said rosmarinic acid.
4. The herbal drug composition for the cartilage protection according to claim 1, wherein said oleanolic acid is present in the range of from 2.0 to 6.0 wt. % to the total composition.
5. The herbal drug composition for the cartilage protection according to claim 3, wherein said 4-hydroxybenzoic acid is present in the range of from 0.01 to 0.04 wt. % to the total composition.
6. A cartilage protective comprising the herbal drug composition selected from the possible combinations consisting of said claims 1-5 as an active ingredient for cartilage protection and arthritis therapeutic treatment.
7. The cartilage protective according to claim 6, wherein said cartilage protective is formulated in the form of tablets or soft gelatin capsules for oral administration, injection solutions, ointments, or transdermals.
8. The cartilage protective according to claim 7, wherein the dosage of said tablet or soft gelatin capsule for oral administration is in the range of from 50 to 2400 mg daily.
US10/478,048 2001-05-18 2002-01-04 Herbal drug composition for cartilage protection Abandoned US20040146593A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/400,784 US8652537B2 (en) 2001-05-18 2012-02-21 Herbal drug composition for cartilage protection

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR2001-0027231 2001-05-18
KR10-2001-0027231A KR100483707B1 (en) 2001-05-18 2001-05-18 Cartilage protective ingredients from medicinal plants and their composition
PCT/KR2002/000010 WO2002094301A1 (en) 2001-05-18 2002-01-04 Herbal drug composition for cartilage protection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/400,784 Continuation US8652537B2 (en) 2001-05-18 2012-02-21 Herbal drug composition for cartilage protection

Publications (1)

Publication Number Publication Date
US20040146593A1 true US20040146593A1 (en) 2004-07-29

Family

ID=19709626

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/478,048 Abandoned US20040146593A1 (en) 2001-05-18 2002-01-04 Herbal drug composition for cartilage protection
US13/400,784 Expired - Lifetime US8652537B2 (en) 2001-05-18 2012-02-21 Herbal drug composition for cartilage protection

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/400,784 Expired - Lifetime US8652537B2 (en) 2001-05-18 2012-02-21 Herbal drug composition for cartilage protection

Country Status (16)

Country Link
US (2) US20040146593A1 (en)
EP (1) EP1392338B1 (en)
JP (1) JP4106418B2 (en)
KR (1) KR100483707B1 (en)
CN (1) CN100448460C (en)
AT (1) ATE394112T1 (en)
AU (1) AU2002219677B2 (en)
BR (1) BRPI0209909B8 (en)
CA (1) CA2447712C (en)
DE (1) DE60226433D1 (en)
DK (1) DK1392338T3 (en)
ES (1) ES2305296T3 (en)
HK (1) HK1069328A1 (en)
MX (1) MXPA03010447A (en)
PT (1) PT1392338E (en)
WO (1) WO2002094301A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040143415A1 (en) * 2003-01-09 2004-07-22 Jay Gregory D. Joint friction sensing
US20090076143A1 (en) * 2007-09-17 2009-03-19 Chi-Huey Wong Compositions and methods for treating inflammation and inflammation-related disorders by plectranthus amboinicus extracts
US20120135094A1 (en) * 2009-05-14 2012-05-31 Rutgers, The State University Of New Jersey Oregano and mint anti-inflammatory compositions and methods

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100858733B1 (en) * 2002-04-22 2008-09-17 에스케이케미칼주식회사 Cartilage protective ingredients from Trichosanthes kirilowii
KR100656571B1 (en) * 2004-06-16 2006-12-13 비타민하우스알앤비티(주) Composition for preventation and treatment of degenerative arthritis
EP2247290A1 (en) * 2008-02-25 2010-11-10 Nestec S.A. Polyphenols for the treatment of cartilage disorders
CN102426207B (en) * 2011-11-08 2014-11-12 华南农业大学 Detection method for flavone component in clematis filamentosa dunn, and application thereof
WO2014171740A1 (en) * 2013-04-17 2014-10-23 에스케이케미칼주식회사 Pharmaceutical composition for treating or alleviating arthritis, containing aceclofenac or pharmaceutically acceptable salt thereof, and extract comprising clematis florida, paeonia lactiflora pall. and prunella vulgaris var. lilacina nakai
CN104997864A (en) * 2015-07-26 2015-10-28 四川金堂海纳生物医药技术研究所 Oral medicine for treating lumbar muscle degeneration and preparation method thereof
JP2017109942A (en) * 2015-12-15 2017-06-22 日本製粉株式会社 Composition for promoting knee joint function improvement action and skeletal muscle function enhancement action by resistance training, comprising oleanane-type triterpene as active ingredient, and using no training equipment
KR101974338B1 (en) * 2016-07-21 2019-05-02 서울대학교산학협력단 Hypoallergenic Cosmetic composition comprising the extract of Clematis apiifolia DC. or Silene armeria L. for alleviating skin inflammation
KR102618628B1 (en) 2020-11-24 2023-12-27 에스케이케미칼 주식회사 Pharmaceutical composition comprising high amount of an active ingredient derived from herbal substances
CN116744907A (en) 2020-11-24 2023-09-12 Sk化学公司 Pharmaceutical composition comprising high levels of active principles of natural origin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02207023A (en) * 1989-02-07 1990-08-16 Moriyuki Hiramatsu Herb drug extract, its preparation and use thereof
KR0180567B1 (en) * 1995-12-29 1999-03-20 김준웅 Method for extracting and purifying effective reactive from compound crude drug
CA2185983C (en) * 1996-09-19 2004-04-13 Wie-Jong Kwak Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition
KR19980072723A (en) * 1997-03-07 1998-11-05 한기학 Chinese herbal compositions and pharmaceutical preparations thereof
KR19990042936A (en) * 1997-11-28 1999-06-15 배오성 Smokers for the treatment of diseases and methods of treating the diseases using the same
DE69930619T2 (en) * 1998-05-16 2006-12-28 Mogam Biotechnology Research Institute, Yongin USE OF ROSMARIC ACID AND ITS DERIVATIVES AS IMMUNOSUPPRESSOR OR AS INHIBITOR OF SH-2-MEDIATED PROCESSES
KR20000072988A (en) * 1999-05-04 2000-12-05 허영섭 Use of rosmarinic acid and derivatives thereof as an immunosuppressant and an inhibitor of SH2-mediated process
KR19990083970A (en) * 1999-09-03 1999-12-06 정진호 Phamaceutical compositions for treating rheumatism and method for production thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040143415A1 (en) * 2003-01-09 2004-07-22 Jay Gregory D. Joint friction sensing
US7415381B2 (en) * 2003-01-09 2008-08-19 Rhode Island Hospital, A Lifespan Partner Joint friction sensing
US20090076143A1 (en) * 2007-09-17 2009-03-19 Chi-Huey Wong Compositions and methods for treating inflammation and inflammation-related disorders by plectranthus amboinicus extracts
US8105636B2 (en) 2007-09-17 2012-01-31 Academia Sinica Compositions and methods for treating inflammation and inflammation-related disorders by Plectranthus amboinicus extracts
US20120135094A1 (en) * 2009-05-14 2012-05-31 Rutgers, The State University Of New Jersey Oregano and mint anti-inflammatory compositions and methods

Also Published As

Publication number Publication date
CN1529609A (en) 2004-09-15
KR100483707B1 (en) 2005-04-18
BRPI0209909B8 (en) 2021-05-25
CN100448460C (en) 2009-01-07
JP2004529961A (en) 2004-09-30
KR20020088211A (en) 2002-11-27
US20120148693A1 (en) 2012-06-14
CA2447712C (en) 2011-02-22
ES2305296T3 (en) 2008-11-01
DK1392338T3 (en) 2008-08-04
ATE394112T1 (en) 2008-05-15
US8652537B2 (en) 2014-02-18
EP1392338A1 (en) 2004-03-03
CA2447712A1 (en) 2002-11-28
HK1069328A1 (en) 2005-05-20
EP1392338B1 (en) 2008-05-07
DE60226433D1 (en) 2008-06-19
PT1392338E (en) 2008-06-18
BRPI0209909B1 (en) 2015-08-25
WO2002094301A1 (en) 2002-11-28
MXPA03010447A (en) 2004-04-02
BR0209909A (en) 2004-07-27
KR100483707B9 (en) 2021-07-29
AU2002219677B2 (en) 2007-03-01
JP4106418B2 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
US8652537B2 (en) Herbal drug composition for cartilage protection
EP0832652B1 (en) Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition
KR100847439B1 (en) Trachelospermi caulis extracts compositions for treating or preventing inflammatory diseases
AU2002219677A1 (en) Herbal drug composition for cartilage protection
KR20110006642A (en) Anti-arthritis and cartilage protective herbal preparations containing reduced cucurbitacin b
CN102988457A (en) Total flavone extract of lonicera macranthoides leaves, and preparation method and application thereof
CN101982184A (en) Preparation method of taraxacum extract
KR0180567B1 (en) Method for extracting and purifying effective reactive from compound crude drug
KR100847440B1 (en) Drug of herbal mixture for treating or preventing inflammatory diseases
CN103463333B (en) Aloe-cactus-peach leaf gel preparation and preparation method thereof
CN1748725A (en) Process for preparing semen momordicae seed extract containing triterpene saponin component
KR101026524B1 (en) A medicinal herbs composition for protective stomach and intestines
KR101093731B1 (en) Liriope platyphylla extracts compositions for treating or preventing inflammatory diseases
KR20090095974A (en) composition of Korean medicine for bone
CN107308342B (en) Dendrobium eye drops for treating conjunctivitis and keratitis caused by bacterial infection
KR100858733B1 (en) Cartilage protective ingredients from Trichosanthes kirilowii
KR20030082764A (en) Articulation protective ingredients from medicinal plant and their composition
CN105617024B (en) a Chinese medicinal composition for treating psoriasis, and its preparation method
KR20030021714A (en) Herb complex composition comprising anti-toxic extract ingredients and its preparing method
CN107519238A (en) Analgesia for liver cancer and breast cancer end-stage patients is lengthened the life parenteral solution and its application
DE69635791T2 (en) Process for extracting and purifying biologically active ingredients from a medicinal plant mixture and plant extract composition
KR101093729B1 (en) Chimaphila japonica miq extracts compositions for treating or preventing inflammatory diseases
KR20030082763A (en) Articulation protective ingredients from medicinal plant and their composition
Linna et al. Modern research and application analysis of honeysuckle
Xia et al. Comparison of the Polysaccharide Content of Cultivated Dioscorea nipponica Makino and Research on Pharmacologic Activity of Polysaccharide

Legal Events

Date Code Title Description
AS Assignment

Owner name: SK CHEMICALS CO., LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAN, CHANG-KYUN;KWAK, WIE-JONG;JOUNG, KI WON;AND OTHERS;REEL/FRAME:015174/0274

Effective date: 20031115

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION